These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

533 related articles for article (PubMed ID: 25583246)

  • 21. Tonically active NMDA receptors--a signalling mechanism critical for interneuronal excitability in the CA1 stratum radiatum.
    Riebe I; Seth H; Culley G; Dósa Z; Radi S; Strand K; Fröjd V; Hanse E
    Eur J Neurosci; 2016 Jan; 43(2):169-78. PubMed ID: 26547631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia.
    Labrie V; Roder JC
    Neurosci Biobehav Rev; 2010 Mar; 34(3):351-72. PubMed ID: 19695284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Positive and negative symptoms in schizophrenia: the NMDA receptor hypofunction hypothesis, neuregulin/ErbB4 and synapse regression.
    Bennett M
    Aust N Z J Psychiatry; 2009 Aug; 43(8):711-21. PubMed ID: 19629792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia.
    Wang X; Pinto-Duarte A; Sejnowski TJ; Behrens MM
    Antioxid Redox Signal; 2013 Apr; 18(12):1444-62. PubMed ID: 22938164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Molecular pathology of schizophrenia].
    Uezato A; Nishikawa T
    Nihon Rinsho; 2013 Apr; 71(4):591-8. PubMed ID: 23678584
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of striatal dopamine release by glycine transport inhibitors.
    Javitt DC; Hashim A; Sershen H
    Neuropsychopharmacology; 2005 Apr; 30(4):649-56. PubMed ID: 15688094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Decreased levels of D-aspartate and NMDA in the prefrontal cortex and striatum of patients with schizophrenia.
    Errico F; Napolitano F; Squillace M; Vitucci D; Blasi G; de Bartolomeis A; Bertolino A; D'Aniello A; Usiello A
    J Psychiatr Res; 2013 Oct; 47(10):1432-7. PubMed ID: 23835041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The GABA-glutamate connection in schizophrenia: which is the proximate cause?
    Coyle JT
    Biochem Pharmacol; 2004 Oct; 68(8):1507-14. PubMed ID: 15451393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early-life lead exposure recapitulates the selective loss of parvalbumin-positive GABAergic interneurons and subcortical dopamine system hyperactivity present in schizophrenia.
    Stansfield KH; Ruby KN; Soares BD; McGlothan JL; Liu X; Guilarte TR
    Transl Psychiatry; 2015 Mar; 5(3):e522. PubMed ID: 25756805
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia.
    du Bois TM; Huang XF
    Brain Res Rev; 2007 Feb; 53(2):260-70. PubMed ID: 17014910
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia.
    Ju P; Cui D
    Acta Biochim Biophys Sin (Shanghai); 2016 Mar; 48(3):209-19. PubMed ID: 26837414
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [NMDA-type glutamate receptor and schizophrenia].
    Nishikawa T; Ishiwata S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2013 Nov; 33(5-6):217-24. PubMed ID: 25069261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multi-Scale Understanding of NMDA Receptor Function in Schizophrenia.
    Hyun JS; Inoue T; Hayashi-Takagi A
    Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32796766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic data supporting the NMDA glutamate receptor hypothesis for schizophrenia.
    Schwartz TL; Sachdeva S; Stahl SM
    Curr Pharm Des; 2012; 18(12):1580-92. PubMed ID: 22280435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The NMDA receptor may participate in widespread suppression of circuit level neural activity, in addition to a similarly prominent role in circuit level activation.
    Fitzgerald PJ
    Behav Brain Res; 2012 Apr; 230(1):291-8. PubMed ID: 22342923
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia.
    Greene R
    Hippocampus; 2001; 11(5):569-77. PubMed ID: 11732709
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Schizophrenia: more evidence for less glutamate.
    Morrison PD; Pilowsky LS
    Expert Rev Neurother; 2007 Jan; 7(1):29-31. PubMed ID: 17187494
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia.
    Hahn CG; Wang HY; Cho DS; Talbot K; Gur RE; Berrettini WH; Bakshi K; Kamins J; Borgmann-Winter KE; Siegel SJ; Gallop RJ; Arnold SE
    Nat Med; 2006 Jul; 12(7):824-8. PubMed ID: 16767099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Evidence on the key role of the metabotrobic glutamatergic receptors in the pathogenesis of schizophrenia: a "breakthrough" in pharmacological treatment].
    Pannese R; Minichino A; Pignatelli M; Delle Chiaie R; Biondi M; Nicoletti F
    Riv Psichiatr; 2012; 47(2):149-69. PubMed ID: 22622251
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lamina-specific abnormalities of NMDA receptor-associated postsynaptic protein transcripts in the prefrontal cortex in schizophrenia and bipolar disorder.
    Beneyto M; Meador-Woodruff JH
    Neuropsychopharmacology; 2008 Aug; 33(9):2175-86. PubMed ID: 18033238
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.